Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Geovax Labs (GOVX)

Geovax Labs (GOVX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth FinancialNewsMedia - Thu Jun 20, 9:00AM CDT

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GOVX),(NYSE:GSK),(NASDAQ:AZN),(NYSE:MRK) EQNX::TICKER_END

ONCY : 1.0100 (+2.02%)
ONC.TO : 1.37 (unch)
GOVX : 3.16 (-4.53%)
GSK : 38.22 (+0.03%)
AZN : 76.68 (-0.40%)
MRK : 127.21 (-0.40%)
Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth GlobeNewswire - Thu Jun 20, 9:00AM CDT

ONCY : 1.0100 (+2.02%)
ONC.TO : 1.37 (unch)
GOVX : 3.16 (-4.53%)
GSK : 38.22 (+0.03%)
AZN : 76.68 (-0.40%)
MRK : 127.21 (-0.40%)
GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update Globe Newswire - Wed Aug 3, 2022

Advancing Phase 2 Clinical Trials for COVID-19 and Immuno-Oncology Evaluation of Company’s Vaccine Platform Against Monkeypox Underway ATLANTA, GA,...

GOVX : 3.16 (-4.53%)
GOVXW : 0.1195 (-1.24%)
GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate Against Sudan Ebolavirus Showing 100% Protection With a Single Immunization Globe Newswire - Thu Jul 28, 2022

ATLANTA, GA, July 28, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human vaccines and...

GOVXW : 0.1195 (-1.24%)
GOVX : 3.16 (-4.53%)
GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update Globe Newswire - Tue Jul 26, 2022

Conference Call to be Held Wednesday, August 3, at 4:30 p.m. Eastern Time ATLANTA, GA, July 26, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs,...

GOVXW : 0.1195 (-1.24%)
GOVX : 3.16 (-4.53%)
GeoVax to Present at BIO International Convention 2022 Globe Newswire - Tue Jun 7, 2022

Company to Provide Updates on Phase 2 Clinical Trials for COVID-19 Vaccine and Immuno-oncology/Gedeptin® Atlanta, GA, June 07, 2022 (GLOBE NEWSWIRE)...

GOVXW : 0.1195 (-1.24%)
GOVX : 3.16 (-4.53%)
GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules Globe Newswire - Wed May 25, 2022

Atlanta, GA, May 25, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing...

GOVXW : 0.1195 (-1.24%)
GOVX : 3.16 (-4.53%)
GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China Globe Newswire - Tue May 24, 2022

Atlanta, GA, May 24, 2022 (GLOBE NEWSWIRE) -- IND-Enabling Studies Underway in the United States for MVA-VLP-MUC1 Vaccine Candidate via NewMediaWire...

GOVXW : 0.1195 (-1.24%)
GOVX : 3.16 (-4.53%)
GeoVax Announces Upcoming Presentations at Scientific Conferences Globe Newswire - Wed May 4, 2022

ATLANTA, GA, May 04, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire –GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human vaccines and...

GOVXW : 0.1195 (-1.24%)
GOVX : 3.16 (-4.53%)
GeoVax Announces Issuance of Malaria Vaccine Patent Globe Newswire - Tue Apr 26, 2022

GeoVax’s Unique Multi-Antigenic Vaccine Approach Designed to Provide Stronger, Broader Protection Against Malaria Atlanta, GA, April 26, 2022 (GLOBE...

GOVXW : 0.1195 (-1.24%)
GOVX : 3.16 (-4.53%)

Barchart Exclusives

1 No-Brainer Value Stock That Looks Set to Recover From Its Slump Barchart - 28 minutes ago
PayPal's valuations look quite compelling after its massive underperformance, and the fintech name looks like a good value stock to buy at these price levels. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot